MedPath

Choice of Modality of Follow up for Medication Abortion

Not Applicable
Terminated
Conditions
Abortion in First Trimester
Registration Number
NCT04056637
Lead Sponsor
Stanford University
Brief Summary

This study will assess the impact of providing medication abortion-seeking clients a choice for follow-up in practice. Clients presenting at or less than 63 days pregnant (based on last menstrual period) at the study site for first trimester medication abortion will be invited to participate. We hypothesize that providing clients with flexible follow-up options will improve follow-up rates.

This study is not to assess efficacy or safety of follow-up methods--that has been well established in practice and research. This is to assess choice of follow-up.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
26
Inclusion Criteria
  • Eligible for medication abortion <63 days gestational age
  • In general good health
  • English or Spanish speaking competency
  • Willing and able to sign consent forms
Exclusion Criteria
  • Clients less than 18 years of age.
  • Any client not meeting the inclusion criteria listed above will be excluded from participating in the trial.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Percent follow-up after medication abortion by group5-14 days following mifepristone administration

To compare rates of follow-up among clients who are instructed to come back to the clinic for in-person ultrasound medication abortion follow-up to clients who are given options for follow-up, including in-person ultrasound, repeat serum beta-hCG and MLPT

Secondary Outcome Measures
NameTimeMethod
Percent follow-up after medication abortion by follow-up type5-14 days following mifepristone administration

To compare the overall proportion of follow-up completion among clients choosing their preferred method of follow-up (in-person ultrasound, repeat serum beta-hCG, MLPT strategy) (study period) to clients given only the option for in-person follow-up

Trial Locations

Locations (1)

Stanford Health Care

🇺🇸

Stanford, California, United States

Stanford Health Care
🇺🇸Stanford, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.